Sotrovimab (LS)
Sotrovimab (VIR 7831) (LS) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. The Fc region of Sotrovimab (LS) incorporates the M428L and N434S mutations, which are intended to extend its serum half-life. Sotrovimab (LS) could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
SARS-CoV-2
In Vitro
Sotrovimab (LS) neutralizes both SARS-CoV-2 and SARS-CoV, but does not directly block virus receptor binding[2].
Sotrovimab (LS) (100 μg/mL, injected for 200 s, v=30 μL/min) binds efficiently to surface-expressed SARS-CoV-2 S[3].
Sotrovimab (LS) (0.3 ng/mL-20 mg/mL; 30 min) neutralizes SARS-CoV-2 pseudo-typed virus in vitro, and also against the Alpha, Beta, Gamma, Delta and Kappa variant viruses with IC50s of 187.2 ng/mL, 71.9 ng/mL, 73.11 ng/mL, 51.3 ng/mL, and 118.64 ng/mL, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
SMILES
[Sotrovimab (LS)]
-
Synonyms
VIR-7831 (LS); GSK-4182136 (LS)
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Gupta A, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950. [Content Brief]
[2]. Case JB, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 Jul 2;13(1):3824. [Content Brief]
[4]. Aweda TA, et al. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging. 2022 Oct 28:1–12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)